Chemomab appoints Dale Pfost as CEO; co-founder Adi Mor becomes CSO

Chemomab Therapeutics Ltd.

Dr. Dale Pfost appointed CEO, subject to shareholder approval expected Q4 2021.
Dr. Adi Mor steps down as CEO, continues as Chief Scientific Officer and board member.
Pfost brings 35 yrs experience; served as CEO of six biotech firms, including public companies.
Pfost expected to join board and become Chairman in 2022 (subject to shareholder approval).
Company has two Phase 2 studies underway; third expected to start in coming months.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dale Pfost

Chief Executive Officer

CMMB · Chemomab Therapeutics Ltd.

Filed: September 2, 2021, 7:59 PM ET

On September 2, 2021, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company.

Role change

Adi Mor

Chief Scientific Officer

CMMB · Chemomab Therapeutics Ltd.

Successor: Dale Pfost
Filed: September 2, 2021, 7:59 PM ET

Dr. Pfost will replace Dr. Adi Mor, who will step down from her role as Chief Executive Officer, effective as of the appointment of Dr. Pfost, and who will continue to be employed by the Company as Chief Scientific Officer where she will oversee scientific strategy and R&D operations.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dale Pfost was appointed as Chief Executive Officer at Chemomab Therapeutics Ltd..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On September 2, 2021, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Adi Mor changed role as Chief Scientific Officer at Chemomab Therapeutics Ltd..

Action: stepped down as CEO and continued as Chief Scientific Officer
Role: Chief Scientific Officer

Exact text from the filing

Dr. Pfost will replace Dr. Adi Mor, who will step down from her role as Chief Executive Officer, effective as of the appointment of Dr. Pfost, and who will continue to be employed by the Company as Chief Scientific Officer where she will oversee scientific strategy and R&D operations.

View on SEC.gov

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-21-002894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.